Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/52560
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ee C. | - |
dc.contributor.author | Tay C.T. | - |
dc.date.accessioned | 2024-10-16T01:56:16Z | - |
dc.date.available | 2024-10-16T01:56:16Z | - |
dc.date.copyright | 2024 | - |
dc.date.issued | 2024-10-08 | en |
dc.identifier.citation | Australian Prescriber. 47(4) (pp 109-112), 2024. Date of Publication: August 2024. | - |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/52560 | - |
dc.description.abstract | Polycystic ovary syndrome is a common and frequently undiagnosed female endocrine disorder that is associated with diverse symptoms and features, and an increased risk of long-term chronic diseases such as type 2 diabetes and cardiovascular disease. Pharmacotherapy for polycystic ovary syndrome should be directed at the key concerns of the individual patient. The combined oral contraceptive pill or metformin may be prescribed for irregular periods. The combined oral contraceptive pill is preferred over antiandrogens for treatment of hirsutism and acne. Metformin is of benefit for reducing excess body weight and improving hormonal and metabolic outcomes in those with high metabolic risk (e.g. body mass index greater than 25 kg/m2). Inositol appears to have limited benefits for metabolic outcomes, although it is associated with fewer adverse effects than metformin. Modification of lifestyle factors is important as part of a holistic approach to managing polycystic ovary syndrome. Anti-obesity drugs may be considered for weight management in addition to lifestyle interventions.Copyright © 2024 Therapeutic Guidelines Ltd. | - |
dc.publisher | Therapeutic Guidelines Ltd | - |
dc.relation.ispartof | Australian Prescriber | - |
dc.subject.mesh | acne | - |
dc.subject.mesh | anxiety | - |
dc.subject.mesh | cardiovascular disease | - |
dc.subject.mesh | endocrine disease | - |
dc.subject.mesh | endometrium cancer | - |
dc.subject.mesh | hirsutism | - |
dc.subject.mesh | hyperandrogenism | - |
dc.subject.mesh | insulin resistance | - |
dc.subject.mesh | menstrual cycle | - |
dc.subject.mesh | non insulin dependent diabetes mellitus | - |
dc.subject.mesh | obstructive sleep apnea | - |
dc.subject.mesh | ovary polycystic disease | - |
dc.title | Pharmacological management of polycystic ovary syndrome. | - |
dc.type | Article | - |
dc.identifier.affiliation | Monash University - Monash Centre for Health Research and Implementation | - |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.18773/AUSTPRESCR.2024.030 | - |
dc.publisher.place | Australia | - |
dc.identifier.institution | (Ee) NICM Health Research Institute, Western Sydney University, Penrith, NSW, Australia | - |
dc.identifier.institution | (Tay) Monash Health, Melbourne, Australia | - |
dc.identifier.institution | (Tay) Monash Centre for Health Research and Implementation, Monash University, Melbourne, Australia | - |
dc.identifier.affiliationmh | (Tay) Monash Health, Melbourne, Australia | - |
dc.identifier.affiliationmh | (Tay) Monash Centre for Health Research and Implementation, Monash University, Melbourne, Australia | - |
item.openairetype | Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.